Search

Copyright of Food & Machinery is the property of Food & Machinery Editorial Office and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Chinese Journal of Preventive Veterinary Medicine / Zhongguo Yufang Shouyi Xuebao is the property of Chinese Journal of Preventive Veterinary Medicine Editorial Office and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Chinese Journal of Preventive Veterinary Medicine / Zhongguo Yufang Shouyi Xuebao is the property of Chinese Journal of Preventive Veterinary Medicine Editorial Office and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Chinese Journal of Preventive Veterinary Medicine / Zhongguo Yufang Shouyi Xuebao is the property of Chinese Journal of Preventive Veterinary Medicine Editorial Office and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

目的 总结 SCN2A基因突变早发癫痫性脑病（EOEE）的有效诊断及治疗方法。方法 对 1例 SCN2A基 因突变EOEE患儿的临床资料作回顾性分析。结果 1例1个月4天患儿，因“1天内无热抽搐4次”就诊。患儿生后 3天时无明显诱因下出现抽搐，诊断为新生儿惊厥，予口服苯巴比妥片治疗。本次入院后继续予以苯巴比妥治疗3 天，视频脑电图提示多灶性尖波发放。结合病史、查体及辅助检查结果，考虑为癫痫，使用左乙拉西坦口服液控制癫 痫发作。为明确患儿病因，对患儿及其父母的癫痫基因 Panel、线粒体基因组、癫痫相关拷贝数变异进行高通量测 序，基因检测结果显示，患儿 SCN2A 基因出现疑似致病变异 c. 468G>C（p. Lys156Asn），为错义变异；患儿父母该位 点均未发现异常，患儿 SCN2A 基因突变为新生突变。结合患儿起病年龄、发作形式及生长发育情况，明确诊断为 EOEE，在原治疗方案基础上加用生酮饮食（KD）治疗。经KD治疗后好转出院，目前患儿癫痫发作已完全控制，但智 力及运动发育稍有落后。结论 EOEE患儿可伴有SCN2A基因突变，基因检测可明确突变类型，结合临床表现和基 因检测结果可明确诊断，当苯巴比妥不能控制癫痫发作时，可早期应用KD治疗。 [ABSTRACT FROM AUTHOR]

Copyright of Chinese Journal of Applied Entomology is the property of Chinese Journal of Applied Entomology, Editorial Department and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Objective To observe the effect of levetiracetam on the expression of multiple drug resistance gene 1(MDR1) and P-glycoprotein(P-gp) in the peripheral blood mononuclear cells of children with refractory epilepsy, and to investigate its significance. Methods Fifty children with refractory epilepsy were selected, and they were treated with levetiracetam as an addition therapy on the basis of the original antiepileptic programme. We collected the peripheral venous blood and extracted the mononuclear cells before adding levetiracetam and 6 and 12 months after treatment. The expression of MDR1 mRNA was detected by RT-PCR and the expression of P-gp was tested by Western blotting. Results The relative expression of MDR1 mRNA and P-gp in the peripheral blood mononuclear cells of children with refractory epilepsy treated with extra levetiracetam for 6 and 12 months was significantly lower than that of children before the treatment of levetiracetam(both P<0.05). Although the relative expression of MDR1 mRNA and P-gp in the peripheral blood mononuclear cells treated with levetiracetam for 6 and 12 months showed no statistical difference, but there was a downward trend(both P>0.05). Conclusion Levetiracetam can down-regulate the expression of MDR1 mRNA and P-gp in the peripheral blood mononuclear cells of children with refractory epilepsy, which provides a new clinical idea for the treatment of refractory epilepsy. [ABSTRACT FROM AUTHOR]

Copyright of Chinese Journal of Preventive Veterinary Medicine / Zhongguo Yufang Shouyi Xuebao is the property of Chinese Journal of Preventive Veterinary Medicine Editorial Office and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)